Breakwater Capital Group Buys 55 Shares of Danaher Co. (NYSE:DHR)

Breakwater Capital Group boosted its holdings in Danaher Co. (NYSE:DHR) by 2.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,229 shares of the conglomerate’s stock after buying an additional 55 shares during the period. Breakwater Capital Group’s holdings in Danaher were worth $517,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in DHR. Banco Santander S.A. bought a new stake in shares of Danaher in the 3rd quarter worth approximately $683,000. First Citizens Bank & Trust Co. boosted its position in shares of Danaher by 0.6% during the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock valued at $6,156,000 after acquiring an additional 149 shares in the last quarter. Parkside Financial Bank & Trust increased its stake in Danaher by 4.8% in the third quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock valued at $764,000 after acquiring an additional 142 shares during the period. Keybank National Association OH boosted its holdings in Danaher by 0.5% during the third quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock valued at $137,238,000 after purchasing an additional 2,567 shares in the last quarter. Finally, Pallas Capital Advisors LLC grew its stake in shares of Danaher by 180.5% in the 4th quarter. Pallas Capital Advisors LLC now owns 8,753 shares of the conglomerate’s stock valued at $2,025,000 after purchasing an additional 5,633 shares during the period. Institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In related news, Director Teri List sold 3,289 shares of Danaher stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the transaction, the director now directly owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Teri List sold 3,289 shares of Danaher stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The disclosure for this sale can be found here. Insiders sold a total of 32,957 shares of company stock worth $8,265,802 in the last quarter. 11.10% of the stock is owned by insiders.

Danaher Stock Performance

NYSE:DHR opened at $243.16 on Friday. The stock has a 50 day simple moving average of $249.21 and a 200 day simple moving average of $230.46. The stock has a market cap of $180.07 billion, a P/E ratio of 37.86, a PEG ratio of 3.71 and a beta of 0.83. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $259.00. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The firm had revenue of $6.41 billion for the quarter, compared to the consensus estimate of $6.10 billion. During the same quarter last year, the business posted $2.87 EPS. The company’s revenue was down 10.2% compared to the same quarter last year. Research analysts anticipate that Danaher Co. will post 7.62 earnings per share for the current year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. This is a positive change from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. Danaher’s dividend payout ratio (DPR) is presently 16.90%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on DHR shares. Wolfe Research started coverage on Danaher in a research report on Wednesday, December 13th. They issued a “peer perform” rating on the stock. TheStreet upgraded shares of Danaher from a “c+” rating to a “b-” rating in a research report on Friday, December 8th. HSBC started coverage on Danaher in a research note on Monday, December 18th. They set a “hold” rating on the stock. JPMorgan Chase & Co. lifted their price objective on Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a report on Wednesday, December 20th. Finally, StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Seven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $266.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.